Considerations for peri- and post-menopausal people with SLE

Studies of menopausal hormone therapy (MHT) indicate that it is not associated with a significant increase in flares of SLE.

For people with SLE who have aPL antibodies, the use of estrogen-containing MHT should be carefully weighed against the risk of thromboembolism and cardiovascular diseaseAndreoli, 2017. If someone wishes to avoid systemic MHT and their menopausal symptoms are predominantly genitourinary (eg vaginal atrophy), intravaginal estrogen treatment may be used. For information on nonhormonal therapies for menopause, refer to the Sexual and Reproductive Health Guidelines.